<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01462006</url>
  </required_header>
  <id_info>
    <org_study_id>15282</org_study_id>
    <secondary_id>R01HL098329</secondary_id>
    <nct_id>NCT01462006</nct_id>
  </id_info>
  <brief_title>Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF)</brief_title>
  <official_title>Double-blind Placebo-controlled Pilot Study of Sirolimus in IPF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Idiopathic pulmonary fibrosis (IPF) is an illness characterized by progressive decline in&#xD;
      lung function and premature death from respiratory failure. Fibrocytes are a novel population&#xD;
      of bone marrow-derived circulating progenitor cells that have been shown to traffic to the&#xD;
      lungs and contribute to fibrosis in animal models of pulmonary fibrosis, and whose numbers&#xD;
      correlate with the degree of fibrosis and with survival in human pulmonary fibrosis. The&#xD;
      investigators propose to test the hypothesis that therapy with the mTOR inhibitor, sirolimus,&#xD;
      reduces the number of circulating fibrocytes in patients with IPF. The investigators propose&#xD;
      to test this hypothesis in short-term pilot trial of sirolimus in patients with IPF to&#xD;
      determine its effect on the number and phenotype of circulating fibrocytes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2011</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fibrocytes</measure>
    <time_frame>up to 22 weeks</time_frame>
    <description>change in peripheral blood concentration of CXCR4+ fibrocytes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>number of subjects with drug side-effects</measure>
    <time_frame>up to 22 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <condition>Diffuse Parenchymal Lung Disease</condition>
  <condition>Interstitial Lung Disease</condition>
  <arm_group>
    <arm_group_label>Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus</intervention_name>
    <description>randomized to drug or placebo, followed by washout, followed by crossover</description>
    <arm_group_label>Sirolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>randomized to drug or placebo, followed by washout, followed by crossover</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients 21-85 years of age&#xD;
&#xD;
          2. Individuals diagnosed with IPF, based on:&#xD;
&#xD;
               -  clinical symptoms consistent with idiopathic pulmonary fibrosis (IPF) of &gt; 3&#xD;
                  months duration, plus&#xD;
&#xD;
               -  histologically diagnosed UIP or diagnostic chest high resolution CT features of&#xD;
                  UIP, plus&#xD;
&#xD;
               -  negative workup for known causes of UIP&#xD;
&#xD;
          3. Ability to understand a written informed consent form and comply with the requirements&#xD;
             of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinical features or known diagnosis of an active infection, including untreated&#xD;
             latent tuberculosis&#xD;
&#xD;
          2. Clinical features or known diagnosis of malignancy&#xD;
&#xD;
          3. Known diagnosis of an interstitial lung disease other than IPF including but not&#xD;
             limited to sarcoidosis, hypersensitivity pneumonitis, non-specific interstitial&#xD;
             pneumonia (NSIP).&#xD;
&#xD;
          4. History of clinically significant environmental exposures known to cause interstitial&#xD;
             lung disease (including but not limited to drugs, asbestos, silica, beryllium,&#xD;
             radiation, domestic birds, etc).&#xD;
&#xD;
          5. Diagnosis of any connective tissue disease (including but not limited to scleroderma,&#xD;
             SLE, rheumatoid arthritis) or vasculitides according to the American College of&#xD;
             Rheumatology criteria.&#xD;
&#xD;
          6. Systolic blood pressure &lt; 100 or &gt;145 mm Hg or diastolic blood pressure &lt; 50 or &gt;90&#xD;
             mmHg&#xD;
&#xD;
          7. Evidence of active infection within 1 week prior to enrollment.&#xD;
&#xD;
          8. Recently started (&lt;8 weeks prior to baseline visit) or planned cardiopulmonary&#xD;
             rehabilitation program before conclusion of the study&#xD;
&#xD;
          9. History of unstable or deteriorating cardiac disease, including but not limited to:&#xD;
             myocardial infarction, coronary artery bypass surgery or angioplasty within the past 6&#xD;
             months, congestive heart failure requiring hospitalization within the past 6 months,&#xD;
             or uncontrolled arrhythmia&#xD;
&#xD;
         10. History of unstable or deteriorating neurologic disease, including but not limited to:&#xD;
             TIAs or stroke&#xD;
&#xD;
         11. Pregnant or lactating females. Females of child bearing potential are required to have&#xD;
             a negative serum or urine pregnancy test prior to treatment and agree to practice&#xD;
             abstinence or prevent pregnancy by at least a barrier method of birth control.&#xD;
&#xD;
         12. Liver panel above specific limits at screening: Total bilirubin &gt;1.5-fold upper limit&#xD;
             of normal, AST, ALT or alkaline phosphatase &gt; 3-fold upper limit of normal at&#xD;
             screening.&#xD;
&#xD;
         13. Hematology outside of specified limits, WBC &lt;2,500/ mm3, hematocrit &lt;30, platelets&#xD;
             &lt;100,000/mm3 at screening.&#xD;
&#xD;
         14. Investigational therapy for any indication within 28 days prior to treatment.&#xD;
&#xD;
         15. Current treatment with drugs that are strong inhibitors of CYP3A4 or P-gp, namely&#xD;
             bromocriptine, cimetidine, cisapride, clotrimazole, danazol, diltiazem, fluconazole,&#xD;
             HIV-protease inhibitors (e.g., ritonavir, indinavir), metoclopramide, nicardipine,&#xD;
             troleandomycin, verapamil&#xD;
&#xD;
         16. Inability or unwillingness to comply with the requirements for the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Borna Mehrad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 26, 2011</study_first_submitted>
  <study_first_submitted_qc>October 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2011</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Borna Mehrad, MD</investigator_full_name>
    <investigator_title>Professor, Department of Medicine, Pulmonary and Critical Care</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

